New hope for lung cancer: Immune-Boosting drug combo after Chemo-Radiation
NCT ID NCT05632809
First seen Nov 10, 2025 · Last updated May 17, 2026 · Updated 22 times
Summary
This study tests whether adding the investigational drug NKTR-255 to the standard drug durvalumab can help people with advanced non-small cell lung cancer live longer after chemoradiation. About 39 adults will receive the combination to see if it restores immune cells and improves survival. The goal is to better control the disease, not to cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.